Delivery Order SPE2DB22D3011-SPE2DB25FQ1AY
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension (180 mL), valued at $1,631.48 under firm fixed-price terms. This is a non-set-aside competitive award with an ultimate completion date of July 24, 2025, and performance occurring at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract under the company's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $1,918.40 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities. This is a non-set-aside contract with performance scheduled for completion by August 5, 2025, with the place of performance located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. The delivery order represents a child contract executed under...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $2,915.25. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The contract is scheduled for completion by June 3, 2025, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 29, 2025, with completion scheduled for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $2,050.33 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,314.20 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60ml), with an ultimate completion date of August 1, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $5,913.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), with completion targeted for August 26, 2025. This non-set-aside contract represents a single delivery order execution against AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,918.07 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. This non-competitive delivery order utilizes firm fixed pricing and maintains an ultimate completion date of August 26, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child delivery order, this award falls under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml) at a firm fixed price of $1,681.44. This contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and is scheduled...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 20, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a ceiling value of $1,301.87. This non-competitive, firm fixed-price delivery order is scheduled for completion by May 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract issued under a larger Indefinite Delivery Contract vehicle....
- SPE2DB22D3011Indefinite Delivery Contract
- SPE2DB22D3011-SPE2DB25FQ1AYDelivery Order
The Defense Logistics Agency awarded a $1,375.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 150 ml quantities. The contract, which is non-set-aside and competitively awarded, is scheduled for completion by June 3, 2025, with performance conducted at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a prime vendor agreement valued at $999,999,999 and extending through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company supplies a comprehensive range of pharmaceutical products to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This award of Quillivant XR, a medication used to treat attention deficit hyperactivity disorder, exemplifies AmerisourceBergen's role in fulfilling federal medical supply needs through competitively awarded delivery orders under firm fixed pricing arrangements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.4k | 6/2/25 |